Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations
No Thumbnail Available
Identifiers
Date
2021-11-21
Authors
Bazhenova, Lyudmila
Minchom, Anna
Viteri, Santiago
Bauml, Joshua M.
Ou, Sai-Hong Ignatius
Gadgeel, Shirish M.
Manuel Trigo, Jose
Backenroth, Daniel
Li, Tracy
Londhe, Anil
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier ireland ltd
Metrics
Export
Abstract
Introduction: Real-world clinical outcomes in patients with advanced NSCLC harboring EGFR exon 20 insertion (exon20ins) mutations have not been extensively studied. We conducted a retrospective cohort study to assess the clinical outcomes of EGFR exon20ins compared with common EGFR (cEGFR) mutations. Methods: Adults with advanced NSCLC harboring any EGFR mutations in the NSCLC Flatiron registry (2011 through May 2020) were included. To compare the relative prognosis (prognostic value) of exon20ins vs cEGFR, real-world overall survival (rwOS) was the primary endpoint. Separately, to compare the relative response to tyrosine kinase inhibitor (TKI) treatment (predictive value), real-world progression-free survival (rwPFS) was the primary endpoint. Results: For the prognostic value analysis, 3014 patients with EGFR mutant NSCLC (cEGFR, n = 2833; EGFR exon20ins, n = 181) were eligible. The median (95% CI) rwOS was 16.2 (11.04-19.38) months in the EGFR exon20ins cohort vs 25.5 (24.48-27.04) months in the cEGFR cohort (adjusted HR, 1.75 [1.45-2.131; p
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
Non-small cell lung cancer, Advanced lung cancer, EGFR mutations, EGFR exon 20 insertions, Flatiron registry, Cell lung-cancer, 1st-line treatment, Open-label, Carboplatin-paclitaxel, Phase-iii, Chemotherapy, Afatinib, Adenocarcinoma, Gefitinib, Survival